ARTICLE | Finance
Caldera draws $278M in PIPE, finds quick path from NewCo to NASDAQ
The deal will fund mid-stage development of a bispecific that could improve on ‘efficacy ceiling’ of existing therapies for inflammatory bowel disease
July 29, 2026 8:37 PM UTC
An investor syndicate shares Caldera’s conviction that its bispecific can be a best-in-class therapy for IBD, and has committed to $278 million in fresh funding alongside a reverse merger that will land the start-up on NASDAQ.
Caldera Therapeutics Inc. said Wednesday it will merge with Synlogic Inc. (Pink:SYBX), which has been exploring strategic options for more than a year. That will create a path to the public markets for Caldera, which launched in January with an in-licensed bispecific molecule targeting TL1A and IL23P19...